Gregory Woods, MD
Family Medicine · York, NENPI 1821044066
Payments from drug & device makers
Across 235 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$483
- Amgen$259
- Astellas Pharma US Inc$235
- Johnson & Johnson$107
- Exact Sciences$104
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 88 | $1,325 |
| Novo Nordisk | 38 | $483 |
| Amgen | 19 | $259 |
| Astellas Pharma US Inc | 7 | $235 |
| Johnson & Johnson | 7 | $107 |
| Exact Sciences | 7 | $104 |
| Lilly USA, LLC | 7 | $98 |
| Pfizer | 7 | $89 |
| Philips North America LLC | 6 | $86 |
| Aimmune Therapeutics, Inc. | 3 | $84 |
| Organon | 4 | $58 |
| Bayer | 4 | $56 |
| GSK | 4 | $52 |
| Merck | 3 | $45 |
| Biogen | 2 | $42 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $35 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Medtronic | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 2 | $28 |
| Itamar Medical Inc | 1 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Grifols USA, LLC | 1 | $26 |
| AstraZeneca | 2 | $24 |
| Pacira Pharmaceuticals Incorporated | 1 | $24 |
| Novartis | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Lexicon Pharmaceuticals, Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,617 in reported general payments places this provider in the 85th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 14 | $56,205 |
| EliquisApixaban | 70 | $37,306 |
| XareltoRivaroxaban | 51 | $32,245 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,340 |
| TrulicityDulaglutide | 14 | $21,236 |
| JanuviaSitagliptin Phosphate | 41 | $20,126 |
| MyrbetriqMirabegron | 16 | $12,904 |
| JardianceEmpagliflozin | 17 | $12,254 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,358 |
| LinzessLinaclotide | 11 | $9,846 |
| Aripiprazole | 17 | $7,482 |
| Repatha SureclickEvolocumab | 12 | $6,295 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 19 | $6,094 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 21 | $4,644 |
| Lacosamide | 12 | $4,545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo | $89 | $43,40089 claims |
| GSKTrelegy Ellipta, Shingrix | $52 | $35,98455 claims |
| Johnson & JohnsonXarelto | $107 | $32,24551 claims |
| Lilly USA, LLCTrulicity | $98 | $21,23614 claims |
| MerckJanuvia | $45 | $20,12641 claims |
| Astellas Pharma US IncMyrbetriq | $235 | $12,90416 claims |
| Boehringer IngelheimJardiance | $26 | $12,25417 claims |
| AstraZenecaBreztri Aerosphere | $24 | $10,35817 claims |
| AbbVieLinzess | $1,325 | $9,84611 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $12 | $3,73112 claims |
| Novo NordiskNovolog | $483 | $2,51913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 981 family medicine providers in Nebraska.
Other family medicine in York
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.